US86150R1077
US86150R1077
Stoke Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 184.420.000 | 36.555.000 | 404.5% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 205.010.000 | 137.927.000 | 48.6% | |
| Operating Income | -20.590.000 | -101.372.000 | 79.7% |
| Pretax Income | -6.885.000 | -88.981.000 | 92.3% |
| Net Income Common Stockholders | -6.885.000 | -88.981.000 | 92.3% |
| -- | -- | -- | |
| -- | -- | -- |